more

DaVita (DVA)

(Delayed Data from NYSE)

$137.72 USD

+1.77 (1.30%)

Updated Jul 16, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

Top 27% (67 out of 250)

Industry: Medical - Outpatient and Home Healthcare

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on September 18,2020

DVA vs. CHE: Which Stock Is the Better Value Option?

DaVita HealthCare (DVA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research Published on September 17,2020

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DVAPositive Net Change

Zacks.com featured highlights include: Brinker International, Target, DaVita, TRI Pointe Group and PennyMac Financial Services

by Zacks Equity Research Published on September 15,2020

Zacks.com featured highlights include: Brinker International, Target, DaVita, TRI Pointe Group and PennyMac Financial Services

Buy 4 Beaten-Down MedTech Value Stocks Amid September Selloffs

by Debanjana Dey Published on September 15,2020

Here are some dirt-cheap MedTech value stocks which have been battered by the pandemic-led market meltdown and can be considered for long-term gains.

5 Stocks Near 52-Week Highs That are Poised to Scale Higher

by Anirudha Bhagat Published on September 14,2020

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.

The Zacks Analyst Blog Highlights: AZN, SFM, DVA, BIG and RCII

by Zacks Equity Research Published on September 10,2020

The Zacks Analyst Blog Highlights: AZN, SFM, DVA, BIG and RCII

pharmaceuticals

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research Published on September 09,2020

Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.

medical

4 Stock-Picking Strategies as Tech Rout Roils Market

by Sweta Killa Published on September 09,2020

We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors in the current market environment, reducing the risk of a downside.

Want to Bet on Relative Price Strength? Try These 5 Stocks

by Nilanjan Choudhury Published on September 09,2020

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

The Zacks Analyst Blog Highlights: JPM, DVA, UAL, GPI and GPK

by Zacks Equity Research Published on September 08,2020

The Zacks Analyst Blog Highlights: JPM, DVA, UAL, GPI and GPK

Should Value Investors Buy DaVita HealthCare (DVA) Stock?

by Zacks Equity Research Published on September 07,2020

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVAPositive Net Change

What September Lull? Buy Laggards Instead of Tech Leaders

by Sanghamitra Saha Published on September 04,2020

The S&P 500 posted its worst single-session drop in nearly three months mainly on profit booking. While high-flying tech names were hurt the most, laggards are better positioned.

3 Top Outpatient and Home Healthcare Stocks to Watch Out For

by Trina Mukherjee Published on September 02,2020

Despite the challenges thrown by the COVID-19 pandemic, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, USPH and PNTG are well positioned to gain from the prospects.